About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
ELAGOLIX SODIUM demonstrates a highdimensional biochemical activity framework integrating catalyticdomain modulation, multiaxis signalling interference, mitochondrialnetwork recalibration, redoxequilibrium restructuring, ionflux redistribution, membranepotential modulation, cytoskeletalarchitecture remodelling and transcriptionfactor circuit reprogramming. The compounds molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotidebinding pockets, redoxbuffer matrices and polymeric scaffolding complexesenabling influence across metabolic, genomic, structural and electrophysiological systems.
ELAGOLIX SODIUM may alter phosphorylationflow geometry across ERK, MAPK, JNK, p38 and PI3KAKT axes; reconfigure Gprotein signalstate logic; redistribute Ca²⁺ microdomains; adjust IP/DAG signalling topology; and recalibrate cAMPPKA amplitude. Mitochondrial effects include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, membranepotential polarity shifting, and ERmitochondria stresssignal crosstalk integration.
HighPrecision
- Kinomescale interference mapping & catalyticcascade modelling
- Highresolution molecular docking & conformationaltransition prediction
- UPR/ERstress, mitophagy & autophagicflux regulatory modelling
- Multiomics network reconstruction: RNAseq, metabolomics, proteomics, phosphoproteomics
- Cytoskeletal tensionmapping & polymerturnover analytics
- Advanced cellfate pathway modelling (apoptosis, necroptosis, ferroptosis, parthanatos)
- AIdriven SAR/QSAR predictive compoundperformance optimisation
Toxicodynamics & Hazard Spectrum
- Rapid ROS escalation & antioxidantbuffer collapse
- Mitochondrial fragmentation or ETCaxis suppression
- Severe Na⁺/K⁺/Ca²⁺ ionic-flux destabilisation
- Cytoskeletal depolymerisation & membrane-integrity loss
- Inflammatory hyperactivation (NF-κB, STAT, IRF signalling clusters)
- Activation of multiaxis programmed-cell-death pathways
- Epigenetic drift including methylation/acetylation instability
For expert not intended for biological or therapeutic exposure.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C22H23N3O5S·Na |
|---|---|
| Molecular Weight | 653.6 g/mol |
| CAS Number | 832720-36-2 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | <1 mg/mL |
| Purity | Purity information is available upon request (COA). |
| Synonym | Elagolix sodium; 832720-36-2; Elagolix sodium salt; Orlissa; NBI-56418 NA |
| IUPAC/Chemical Name | sodium 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate |
| InChl Key | DQYGXRQUFSRDCH-UQIIZPHYSA-M |
| InChl Code | InChI=1S/C32H30F5N3O5.Na/c1-19-28(21-11-6-14-26(45-2)29(21)34)30(43)40(18-25(20-9-4-3-5-10-20)38-16-8-15-27(41)42)31(44)39(19)17-22-23(32(35,36)37)12-7-13-24(22)33;/h3-7,9-14,25,38H,8,15-18H2,1-2H3,(H,41,42);/q;+1/p-1/t25-;/m0./s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
